Drug Profile


Alternative Names: S-78989; XMA-005.2; XMA-0052; XOMA-052

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator XOMA
  • Developer IRIS; National Eye Institute; North Shore-Long Island Jewish Health System; Servier; University of Zurich; XOMA
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Interleukin 1 beta inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Behcet's syndrome; Pyoderma; Uveitis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Uveitis
  • Phase II Acne vulgaris; Acute coronary syndromes; Diabetic nephropathies; Giant cell arteritis; Labyrinthitis; Myositis; Osteoarthritis; Schnitzler syndrome; Scleritis
  • Suspended Rheumatoid arthritis
  • No development reported Cancer; Gout; Juvenile rheumatoid arthritis; Type 1 diabetes mellitus; Type 2 diabetes mellitus
  • Discontinued Pyoderma

Most Recent Events

  • 25 Aug 2017 XOMA market-licenses gevokizumab to Novartis worldwide and grants Novartis a license to intellectual property rights for IL-1 beta targeting antibodies for Cardiovascular disorders
  • 09 Jun 2017 Phase II development for Acne vulgaris and Osteoarthritis is ongoing in the US
  • 09 Mar 2016 Servier terminates its licence for gevokizumab (XOMA, Form 10-K, March 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top